Prospective Grant of an Exclusive Patent License: “Treatment of Acute Lymphoblastic Leukemia, T-Cell Lymphoma, and Non-Small Cell Lung Cancer Using the 4A10 Antibody and Fragments Thereof”, 4492 [2019-02442]

Download as PDF 4492 Federal Register / Vol. 84, No. 32 / Friday, February 15, 2019 / Notices Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: February 11, 2019. Natasha Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–02424 Filed 2–14–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of an Exclusive Patent License: ‘‘Treatment of Acute Lymphoblastic Leukemia, T-Cell Lymphoma, and Non-Small Cell Lung Cancer Using the 4A10 Antibody and Fragments Thereof’’ AGENCY: National Institutes of Health, HHS. ACTION: Notice. The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patent Applications listed in the Supplementary Information section of this notice to Fannin Partners L.L.C., (‘‘Fannin’’) of Houston, Texas. DATES: Only written comments and/or applications for a license which are received by the National Cancer Institute’s Technology Transfer Center on or before March 4, 2019 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Lauren Nguyen-Antczak, Sr. Technology Transfer Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, Rm. 1E530, MSC 9702, Bethesda, MD 20892–9702 (for business mail), Rockville, MD 20850– 9702 Telephone: (240)–276–5530; Facsimile: (240)-276–5504 Email: lauren.nguyen-antczak@nih.gov. SUPPLEMENTARY INFORMATION: khammond on DSKBBV9HB2PROD with NOTICES SUMMARY: Intellectual Property Entitled ‘‘IL–7R-alpha Specific Antibodies for Treating Acute Lymphoblastic Leukemia’’ (1) U.S. Provisional Patent Application No. 62/238,612, filed October 7, 2015, corresponding to NIH Ref. No. E–247–2015/0–US–0; (2) International Patent Application No. PCT/US2016/055957, filed October 7, 2016, corresponding to NIH Ref. No. E–247–2015/0–PCT–02; VerDate Sep<11>2014 19:41 Feb 14, 2019 Jkt 247001 (3) Australian Patent Application No. 2016–335750, filed October 7, 2016, corresponding to NIH Ref. No. E–247– 2015/0–AU–03; (4) Canadian Patent Application No. 2997809, filed October 7, 2016, corresponding to NIH Ref. No. E–247– 2015/0–CA–04; (5) European Patent Application No. 16784678.1, filed October 7, 2016, corresponding to NIH Ref. No. E–247– 2015/0–EP–05; (6) U.S. Patent Application No. 15/ 760,193, filed March 14, 2018, corresponding to NIH Ref. No. E–247– 2015/0–US–07; The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America. The prospective exclusive license territory may be where patent applications are filed and the field of use may be limited to ‘‘Treatment of acute lymphoblastic leukemia, T-cell lymphoma, and non-small cell lung cancer using the 4A10 antibody and fragments thereof’’. Additional licensable fields of use are available. The subject technology is directed to monoclonal antibodies (mAb) specific for the alpha chain of the interleukin 7 receptor (IL–7Ra), and corresponding antigen binding fragments, bispecific antibodies, antibody drug conjugates, and encoding nucleic acid thereof. Specifically developed mAbs include those called ‘‘4A10’’ and ‘‘2B8’’. In certain embodiments, the 4A10 antibody can be administered to treat acute lymphoblastic leukemia, particularly those that arise from aberrations in T-cell lineages. This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available. License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 Freedom of Information Act, 5 U.S.C. 552. Dated: February 6, 2019. Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute. [FR Doc. 2019–02442 Filed 2–14–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Office of The Director, National Institutes of Health; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Advisory Committee to the Director, National Institutes of Health. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. Name of Committee: Advisory Committee to the Director, National Institutes of Health. Date: June 13, 2019. Time: 9:00 a.m. to 5:30 p.m. Agenda: NIH Director’s Report, ACD Working Group Reports, Other Business of the Committee. Place: National Institutes of Health, Natcher Building, Conference Room D, 45 Center Drive, Bethesda, MD 20892. Name of Committee: Advisory Committee to the Director, National Institutes of Health. Date: June 14, 2019. Time: 9:00 a.m. to 1:00 p.m. Agenda: ACD Working Group Reports, Other Business of the Committee. Place: National Institutes of Health, Natcher Building, Conference Room D, 45 Center Drive, Bethesda, MD 20892. Contact Person: Gretchen Wood, Staff Assistant, National Institutes of Health, Office of the Director, One Center Drive, Building 1, Room 126, Bethesda, MD 20892, 301–496–4272, Woodgs@od.nih.gov. Name of Committee: Advisory Committee to the Director, National Institutes of Health Date: December 12, 2019. Time: 9:00 a.m. to 5:30 p.m. Agenda: NIH Director’s Report, ACD Working Group Reports, Other Business of the Committee. Place: National Institutes of Health, Natcher Building, Conference Room D, 45 Center Drive, Bethesda, MD 20892. Name of Committee: Advisory Committee to the Director, National Institutes of Health. Date: December 13, 2019. Time: 9:00 a.m. to 1:00 p.m. Agenda: ACD Working Group Reports, Other Business of the Committee. E:\FR\FM\15FEN1.SGM 15FEN1

Agencies

[Federal Register Volume 84, Number 32 (Friday, February 15, 2019)]
[Notices]
[Page 4492]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-02442]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: ``Treatment of 
Acute Lymphoblastic Leukemia, T-Cell Lymphoma, and Non-Small Cell Lung 
Cancer Using the 4A10 Antibody and Fragments Thereof''

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute, an institute of the National 
Institutes of Health, Department of Health and Human Services, is 
contemplating the grant of an Exclusive Patent License to practice the 
inventions embodied in the Patent Applications listed in the 
Supplementary Information section of this notice to Fannin Partners 
L.L.C., (``Fannin'') of Houston, Texas.

DATES: Only written comments and/or applications for a license which 
are received by the National Cancer Institute's Technology Transfer 
Center on or before March 4, 2019 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated an Exclusive Patent License 
should be directed to: Lauren Nguyen-Antczak, Sr. Technology Transfer 
Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, Rm. 
1E530, MSC 9702, Bethesda, MD 20892-9702 (for business mail), 
Rockville, MD 20850-9702 Telephone: (240)-276-5530; Facsimile: (240)-
276-5504 Email: lauren.nguyen-antczak@nih.gov.

SUPPLEMENTARY INFORMATION:

Intellectual Property

    Entitled ``IL-7R-alpha Specific Antibodies for Treating Acute 
Lymphoblastic Leukemia''
    (1) U.S. Provisional Patent Application No. 62/238,612, filed 
October 7, 2015, corresponding to NIH Ref. No. E-247-2015/0-US-0;
    (2) International Patent Application No. PCT/US2016/055957, filed 
October 7, 2016, corresponding to NIH Ref. No. E-247-2015/0-PCT-02;
    (3) Australian Patent Application No. 2016-335750, filed October 7, 
2016, corresponding to NIH Ref. No. E-247-2015/0-AU-03;
    (4) Canadian Patent Application No. 2997809, filed October 7, 2016, 
corresponding to NIH Ref. No. E-247-2015/0-CA-04;
    (5) European Patent Application No. 16784678.1, filed October 7, 
2016, corresponding to NIH Ref. No. E-247-2015/0-EP-05;
    (6) U.S. Patent Application No. 15/760,193, filed March 14, 2018, 
corresponding to NIH Ref. No. E-247-2015/0-US-07;
    The patent rights in these inventions have been assigned and/or 
exclusively licensed to the government of the United States of America.
    The prospective exclusive license territory may be where patent 
applications are filed and the field of use may be limited to 
``Treatment of acute lymphoblastic leukemia, T-cell lymphoma, and non-
small cell lung cancer using the 4A10 antibody and fragments thereof''. 
Additional licensable fields of use are available.
    The subject technology is directed to monoclonal antibodies (mAb) 
specific for the alpha chain of the interleukin 7 receptor (IL-
7R[alpha]), and corresponding antigen binding fragments, bispecific 
antibodies, antibody drug conjugates, and encoding nucleic acid 
thereof. Specifically developed mAbs include those called ``4A10'' and 
``2B8''. In certain embodiments, the 4A10 antibody can be administered 
to treat acute lymphoblastic leukemia, particularly those that arise 
from aberrations in T-cell lineages.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the National 
Cancer Institute receives written evidence and argument that 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially, and may be 
made publicly available.
    License applications submitted in response to this Notice will be 
presumed to contain business confidential information and any release 
of information in these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: February 6, 2019.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2019-02442 Filed 2-14-19; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.